Funding options for a university spinout fall into a small number of distinct categories, and which ones are available — and in what order — depends heavily on how the underlying technology was developed and what stage it has reached. This guide covers the funding pathway from a technology transfer office (TTO) perspective: non-dilutive federal awards, university-internal gap and proof-of-concept funds, licensing income back to the institution, and external dilutive capital (angel and venture investment), plus the conflict-of-interest and Bayh-Dole considerations that make spinout funding different from ordinary personal or company fundraising.
This is deliberately distinct from the general grants lifecycle content on this site: it is not about how a principal investigator applies for a federal research grant to fund a lab’s ongoing work. It is about how an invention moves from a university lab toward a company that can commercialize it, and the specific funding instruments — non-dilutive awards built for that transition, university venture/gap funds, and dilutive private capital — that a TTO, a faculty founder, and a sponsored programs office each have a role in.
The two broad categories: non-dilutive and dilutive
Every funding option a spinout considers falls into one of two categories, and the distinction matters because it determines who ends up owning what.
- Non-dilutive funding does not require giving up equity or ownership. Federal grants and contracts (including SBIR/STTR), university proof-of-concept and gap funds, and some foundation or state economic-development awards are non-dilutive. The tradeoff is that non-dilutive sources typically come with narrower eligibility, defined milestones or deliverables, and — for federal awards — reporting and compliance obligations.
- Dilutive funding — angel investment, venture capital, and most forms of private equity — exchanges capital for an ownership stake (equity) in the company. Dilutive capital is typically faster to deploy and larger in scale than non-dilutive sources once a company has traction, but it changes the company’s cap table and, for a faculty founder, raises institutional conflict-of-interest questions that non-dilutive funding generally does not.
Most spinouts use both, in a fairly predictable sequence: non-dilutive funding (institutional gap funds, then SBIR/STTR) to de-risk the technology early, followed by dilutive capital once the company has enough traction — a working prototype, a signed licensing agreement, early revenue, or a Phase II SBIR award — to support a credible valuation.
Non-dilutive federal funding: SBIR and STTR
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are the primary non-dilutive federal funding route for a university spinout, and they are structured specifically for early-stage technology commercialization rather than basic research. SBIR was created by the Small Business Innovation Development Act of 1982; STTR followed a decade later, in 1992, specifically to let a university-affiliated researcher serve as principal investigator while remaining a university employee — something standard SBIR does not permit, since SBIR requires the PI’s primary employment to be with the small business itself.
Both programs run in three phases: Phase I (feasibility, typically 6-12 months), Phase II (full research and development toward a prototype, up to roughly two years), and Phase III (commercialization — not itself SBIR/STTR-funded, but any follow-on work supported by private capital, non-SBIR federal contracts, or licensing). As of 2026, the statutory guideline caps are approximately $323,090 for Phase I and $2,153,927 for Phase II, though individual agencies can exceed these with an SBA waiver. Eleven federal agencies run SBIR programs; five of those (DoD, NIH/HHS, DOE, NASA, and NSF) also run STTR.
For a faculty-founded spinout, an SBIR/STTR proposal typically depends on groundwork the TTO has already done: an invention disclosure and, if the university elected to retain title under the Bayh-Dole Act, a filed patent application; an exclusive license or option agreement from the university to the spinout; a conflict-of-interest review of the faculty member’s dual role as inventor and company founder; and institutional policy on how any equity or royalty stake the university takes in exchange for the license is structured. See CASRAI’s SBIR dictionary entry and the guide on SBIR/STTR reauthorization for the underlying program mechanics and the periodic lapses in authorization that administrators need to track.
University-internal funding: gap funds and proof-of-concept programs
Before a technology is mature enough for SBIR/STTR or private investment, many institutions run their own internal, non-dilutive funding — commonly called gap funding or proof-of-concept funding — to close the distance between a lab discovery and something a licensee or investor would consider fundable. These programs typically award smaller amounts (often in the low tens of thousands of dollars) against specific technical or market-validation milestones, and are explicitly designed to advance a technology’s Technology Readiness Level (TRL) — the nine-point scale, originally developed by NASA and now used across NSF’s I-Corps program and by universities generally, that describes how far a technology has progressed from basic principles toward a demonstrated, market-ready product.
Because gap funds are internal, the TTO (rather than an external funder) typically sets the eligibility criteria and milestones, which gives an institution more flexibility than federal funding allows — but also means the pool of available capital is usually far smaller and more competitive than SBIR/STTR. The NSF I-Corps program often sits alongside internal gap funding at this stage: I-Corps itself does not fund product development, but the customer-discovery evidence a team produces through it is frequently what makes the case for gap-fund or SBIR/STTR support, or for approaching outside investors at all.
Licensing income as a funding mechanism
Licensing is not typically thought of as “funding” in the venture-capital sense, but it functions as one for a spinout: rather than paying cash for the right to use university intellectual property, a spinout can negotiate an equity stake, deferred royalties, or a combination of both in exchange for the license, preserving the company’s limited early cash for operations instead of licensing fees. This is a defining feature of university spinout deals that a straightforward licensing-to-an-established-company transaction typically does not involve. See CASRAI’s guide on patent licensing for how exclusive license terms, royalty structures, and startup-specific deal terms differ from licenses negotiated with an established company.
The tradeoffs a TTO negotiates here — equity percentage, royalty rate on future sales, minimum annual royalties or diligence milestones the spinout must meet to keep the license, and march-in and government-use rights that survive under Bayh-Dole if the underlying invention was federally funded — directly shape how much external capital the company needs to raise afterward and on what terms.
External dilutive capital: angel investors and venture capital
Once a spinout has enough evidence of feasibility and market interest — commonly a working prototype, a signed license, an SBIR Phase II award, or early revenue — it typically becomes a candidate for outside equity investment.
- Angel investors are individuals investing their own capital, usually at the earliest, highest-risk stage a company is fundable by outside money at all, generally before institutional venture funds are interested. Angel rounds are typically smaller and can close faster than a venture round, with less formal due diligence.
- Venture capital (VC) firms invest institutional or fund capital, typically at a later stage than angels, in exchange for a negotiated equity stake and, often, board representation or other governance rights. VC is generally the largest source of capital available to an early-stage spinout, but it comes with the most extensive due diligence, the most negotiated deal terms (liquidation preferences, anti-dilution provisions, board seats), and an investment thesis built around an eventual exit (acquisition or IPO) — which shapes the company’s growth trajectory in ways non-dilutive funding does not.
Some universities also operate their own affiliated or university-adjacent venture funds that invest directly in spinouts founded on institutional IP, sitting between internal gap funding and outside VC in both check size and formality. Where these exist, they are typically structured to avoid the same conflicts of interest that arise when a faculty inventor becomes an equity holder in their own licensee — see the next section.
Conflict of interest and Bayh-Dole considerations across funding types
Because a faculty founder is simultaneously an inventor, a university employee, and (once equity changes hands) an owner of the company licensing that invention, every funding decision in this sequence intersects with institutional conflict-of-interest policy. A university’s conflict-of-interest review typically covers the faculty member’s equity stake and any consulting or board role in the spinout, how much time they can spend on company activities relative to their university appointment, and whether the university itself holds equity that creates an institutional (not just individual) conflict.
For inventions that trace back to federal funding, Bayh-Dole obligations — timely disclosure, election of title, diligent commercialization efforts, and the government’s retained march-in and use rights — apply regardless of which funding option the spinout later pursues, and they typically get negotiated into the license agreement that sits underneath any subsequent SBIR/STTR award, gap-fund milestone, or investor term sheet. A TTO evaluating funding options for a spinout is, in effect, always evaluating them against this compliance backdrop, not just against the company’s capital needs in isolation.
Frequently asked questions
What funding options are available to a university spinout that don’t require giving up equity?
Non-dilutive options include SBIR/STTR federal awards, university-internal gap or proof-of-concept funds, and some state economic-development or foundation grants. These typically come with narrower eligibility and defined milestones or reporting obligations rather than an equity exchange.
Should a spinout pursue SBIR/STTR funding or venture capital first?
There is no fixed rule, but the common sequence is non-dilutive funding first — institutional gap funds, then SBIR/STTR — to de-risk the technology and produce evidence (a prototype, a Phase II award, early revenue) that supports a stronger valuation before raising dilutive capital. Raising VC too early, before there is much to de-risk, generally means giving up more equity for the same amount of capital.
Can a university itself hold equity in a spinout it licenses technology to?
Yes — taking equity in lieu of, or alongside, cash licensing fees and royalties is common in university spinout deals and is one of the ways a TTO structures licensing as a funding mechanism for a cash-constrained early-stage company. It also introduces an institutional conflict-of-interest question that most universities manage through a formal review process separate from the individual faculty founder’s own conflict review.
Does SBIR/STTR funding affect a university’s Bayh-Dole obligations on the underlying invention?
The Bayh-Dole obligations attach to the invention because of how it was originally created (typically federally funded university research), not because of a later SBIR/STTR award to the spinout. Those obligations — disclosure, election of title, diligent commercialization, government march-in and use rights — are usually addressed in the license agreement between the university and the spinout, independent of whatever funding the spinout subsequently raises.
